Enfuvirtide
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Enfuvirtide |
| DrugBank ID | DB00109 |
| Brand Names (EU) | Fuzeon |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.68% |
Approved Indication (EMA)
Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1-infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens. In deciding on a new regimen for patients who h
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 98.68% | DL |
| 2 | simian immunodeficiency virus infection | 98.18% | DL |
| 3 | feline acquired immunodeficiency syndrome | 98.18% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 97.37% | DL |
| 5 | ulceration of vulva | 89.60% | DL |
| 6 | vulvar neoplasm | 88.74% | DL |
| 7 | vulvitis | 88.56% | DL |
| 8 | commissural lip fistula | 77.79% | DL |
| 9 | osteoradionecrosis of the mandible | 77.43% | DL |
| 10 | burning mouth syndrome | 77.36% | DL |
| 11 | oral leukoedema | 77.36% | DL |
| 12 | postmenopausal atrophic vaginitis | 73.45% | DL |
| 13 | vulvovaginitis | 73.32% | DL |
| 14 | ocular tuberculosis | 70.68% | DL |
| 15 | oral candidiasis | 70.54% | DL |
| 16 | corneal pigmentation | 70.18% | DL |
| 17 | myringitis bullosa hemorrhagica | 69.69% | DL |
| 18 | mycotic corneal ulcer | 68.43% | DL |
| 19 | guttate psoriasis | 68.09% | DL |
| 20 | anogenital human papillomavirus infection | 67.92% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.